Welcome
YOU CAN HELP
 
Do you have any ideas or suggestions about information that you would find helpful to see on this website, please contact one of our: 

Principal Investigators
Dr. François Lamontagne
Dr. Neill Adhikari
Dr Elizabeth Wilcox

Project Leaders
Marie-Hélène Masse
Marie-Claude Battista



 

Thanks to all Participating Centers and collaborators for engaging in this research program!

Thanks to the CCCTG for endorsing this research project.

Clinical Trials NCT03431181
  • Recruitment Started
    The Centre Hospitalier Universitaire de Montréal CHUM has begun recruitment on October 24th 2018 and The Ottawa Hospital will join in November 2018  We are seeking out sites that are interested in joining this exciting study.  Click here for more details about the study.
  • Implementation of the study
    We are very pleased to report that the first site is observing perfect adherence to the protocol so far. The implementation at the lead site has also been a great opportunity to us to pilot the REDCap (eCRF). We are working to incorporate these experiences into our study materials in time to roll‐out to all participating centres.

OVATION Program

The goal of the OVATION program of research is to determine a safe blood pressure target for most patients with vasodilatory hypotension requiring vasopressors.


CONTACT US if you are interested in joining this program of research.

There is a lack of clinical research to guide the treatment of hypotension in critical illness with vasopressors, drugs that can reverse hypotension. Unfortunately, the safety profile of vasopressors and the extreme vulnerability of critically-ill patients leave treating physicians no margin of error. We have an opportunity with the OVATION program to advance our understanding of, and to translate into practice, the optimal strategy to improve outcomes for these patients.

Research Question: Among critically ill adults aged 65 years and older with vasodilatory hypotension, does minimizing vasopressor use by applying lower MAP targets (60-65 mmHg) vs. usual care reduce the proportion of patients who are either dead or dependent on life-sustaining therapies at day 28?

Preliminary Studies

OVATION Survey

OVATION Retrospective Cohort Study

Vasopressor Stewardship

OVATION Pilot Trial

The OVATION Pilot Trial was completed more than one year ahead of schedule! This study addressses the feasibility of the larger definitive study (see below). The pilot enabled us to develop and test implement measures to optimize protocol adherence for the study.  We have established an efficient infrastructure for both Canadian and international participation in the study.

For further information on the pilot refer to our Pilot Trial page.

OVATION Observational Trial

The OVATION Observational trial, was conducted in parallel to the Pilot study, and is also completed.  The purpose of the Observational trial was to describe standard practices in the ICU with regards to vasopressor dosing. Across 6 Canadian centers, the trial recruited 60 critically ill, hypotensive adults receiving vasopressors.

OVATION Trial (Definitive Study)

The results of this trial will provide a stronger foundation for establishing the most suitable treatment strategy for critically ill adults aged 65 years and older with vasodilatory hypotension.

This trial will be conducted under the auspices of the Canadian Critical Care Trials Group, in partnership with the Canadian Critical Care Society (CCCS), the Canadian Association of Critical Care Nurses (CACCN) and the Institute for Safer Medication Practices (ISMP) Canada. Other organization support the OVATION Program and will play specific roles moving forward such as the Canadian Society of Hospital Pharmacists (CSHP), the Canadian Association of Emergency Physicians (CAEP), and the Canadian Agency for Drugs and Technologies in Health (CADTH). We are welcoming input from ICU survivors and healthy citizens.